Aug 4, 2008 | Laboratory News, Laboratory Pathology
Molecular diagnostics has the same potential to create new winners and new losers among in vitro diagnostics (IVD) manufacturers as it does to clinical labs and pathology groups. New molecular assays with the ability to dramatically improve the detection of disease and guide physicians to identify the most effective therapy for individual patients, can radically change the existing market status quo. One example of how molecular tests can open new markets for established IVD vendors is the...
